Literature DB >> 30028826

Brown Recluse Spider Bites in Patients With Neutropenia: A Single-institution Experience.

Diego R Hijano1,2, Daniel Otterson1, Maysam R Homsi3, Yin Su4, Li Tang4, Jeannette Kirby3, Miguela A Caniza1,3.   

Abstract

Brown recluse spider bites can cause local and systemic signs, including rash, dermonecrosis, edema, hemolysis, and acute kidney failure. These are mostly attributed to sphingomyelinase D, the main toxin. To evaluate the severity of the disease in pediatric patients with and without neutropenia, we retrospectively reviewed records of patients treated at St. Jude Children's Research Hospital between 1970 and 2015 and identified 19 patients who met the inclusion criteria. Variables of interest included the type of underlying illness, presence of neutropenia, number of days of hospitalization, disease signs and outcome of the bite, and treatments administered. We used descriptive statistics to summarize the manifestations and severity of spider bites in patients with and without neutropenia. Six patients experienced pain from the bite, 11 had erythema, 7 developed edema, and 5 had fever. The response to spider bites in neutropenic patients was no milder than that in non-neutropenic individuals. Six patients developed systemic complications. Compared with non-neutropenic patients, neutropenic patients had antibiotics prescribed more often and experienced longer hospital stays. Spider bites do not seem to have a different clinical course in neutropenic patients. Therefore, a conservative approach may be best for these patients, with close monitoring and local wound care.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30028826      PMCID: PMC6295234          DOI: 10.1097/MPH.0000000000001253

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  32 in total

Review 1.  The efficacy of antivenom in loxoscelism treatment.

Authors:  Isolete Pauli; Juliana Puka; Ida Cristina Gubert; João Carlos Minozzo
Journal:  Toxicon       Date:  2006-06-30       Impact factor: 3.033

Review 2.  [Cutaneous and visceral loxoscelism: a systematic review].

Authors:  Juan J Manríquez; Sergio Silva
Journal:  Rev Chilena Infectol       Date:  2009-11-09       Impact factor: 0.520

Review 3.  Spider bite.

Authors:  Geoffrey K Isbister; Hui Wen Fan
Journal:  Lancet       Date:  2011-07-15       Impact factor: 79.321

4.  Isolation and identification of Clostridium perfringens in the venom and fangs of Loxosceles intermedia (brown spider): enhancement of the dermonecrotic lesion in loxoscelism.

Authors:  Cristina Leise B Monteiro; Rosália Rubel; Laura Lúcia Cogo; Oldemir C Mangili; Waldemiro Gremski; Silvio S Veiga
Journal:  Toxicon       Date:  2002-04       Impact factor: 3.033

Review 5.  Brown recluse spider bites.

Authors:  T P Forks
Journal:  J Am Board Fam Pract       Date:  2000 Nov-Dec

6.  Brown recluse spider (Loxosceles reclusa) envenomation leading to acute hemolytic anemia in six adolescents.

Authors:  Jenny McDade; Banu Aygun; Russell E Ware
Journal:  J Pediatr       Date:  2010-01       Impact factor: 4.406

7.  Rhabdomyolysis in presumed viscero-cutaneous loxoscelism: report of two cases.

Authors:  Francisco Oscar de Siqueira França; Katia Cristina Barbaro; Regina Célia Rodrigues de Moraes Abdulkader
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 May-Jun       Impact factor: 2.184

8.  Experimental and clinical observations of the effects of cytotoxic chemotherapeutic drugs on wound healing.

Authors:  K I Bland; W E Palin; J A von Fraunhofer; R R Morris; R A Adcock; G R Tobin
Journal:  Ann Surg       Date:  1984-06       Impact factor: 12.969

9.  Sex-linked variation of Loxosceles intermedia spider venoms.

Authors:  K Cristina de Oliveira; R M Gonçalves de Andrade; A L Giusti; W Dias da Silva; D V Tambourgi
Journal:  Toxicon       Date:  1999-01       Impact factor: 3.033

10.  Secondary hemophagocytic lymphohistiocytosis (HLH) from a presumed brown recluse spider bite.

Authors:  Christopher Dandoy; Michael Grimley
Journal:  J Clin Immunol       Date:  2014-04-16       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.